Home Pyridines 100299-08-9
100299-08-9,MFCD22575284
Catalog No.:AA0001EJ
100299-08-9 | 4H-Pyrido[1,2-a]pyrimidin-4-one, 9-methyl-3-(2H-tetrazol-5-yl)-, potassium salt (1:1)
Pack Size
Purity
Availability
Price(USD)
Quantity
  
250mg
98%
in stock  
$131.00   $92.00
- +
1g
98%
in stock  
$285.00   $200.00
- +
  • Technical Information
  • Properties
  • Literature
  • Request for Quotation
  • Q & A
  • Technical Information
  • Properties
  • Literature
Technical Information
Catalog Number:
AA0001EJ
Chemical Name:
4H-Pyrido[1,2-a]pyrimidin-4-one, 9-methyl-3-(2H-tetrazol-5-yl)-, potassium salt (1:1)
CAS Number:
100299-08-9
Molecular Formula:
C10H8KN6O
Molecular Weight:
267.3084
MDL Number:
MFCD22575284
IUPAC Name:
potassium;9-methyl-3-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)pyrido[1,2-a]pyrimidin-4-one
InChI:
InChI=1S/C10H7N6O.K/c1-6-3-2-4-16-9(6)11-5-7(10(16)17)8-12-14-15-13-8;/h2-5H,1H3;/q-1;+1
InChI Key:
NMMVKSMGBDRONO-UHFFFAOYSA-N
SMILES:
Cc1cccn2c1ncc(c2=O)c1n[nH]nn1.[K]
UNII:
497A17OUUE
Properties
Computed Properties
 
Complexity:
495  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
266.032g/mol
Formal Charge:
0
Heavy Atom Count:
18  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
266.305g/mol
Monoisotopic Mass:
266.032g/mol
Rotatable Bond Count:
1  
Topological Polar Surface Area:
72.3A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0

Synonyms
 
9-methyl-3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidin-4-one 
9-TBX 
Alamast 
Pemirolast potassium salt 
BMY 26517 
Alegysal 
UNII-497A17OUUE 
CCRIS 3562 
Pemirolast potassium [USAN:JAN] 
TWT-8152 
BMY-26517 
497A17OUUE 
Alamast 
TBX 
9-Methyl-3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidin-4-one, potassium salt 
DSSTox_CID_26623 
DSSTox_RID_81773 
DSSTox_GSID_46623 
potassium 5-(9-methyl-4-oxo-4H-pyrido[1,2-a]pyrimidin-3-yl)tetrazol-1-ide 
4H-Pyrido(1,2-a)pyrimidin-4-one, 9-methyl-3-(1H-tetrazol-5-yl)-, potassium salt 
9-Methyl-3-(1H-tetrazol-5-yl)-4H-pyrido(1,2-a)pyrimidin-4-one potassium salt 
9-Methyl-3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one Potassium Salt 
9-Methyl-3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one potassium salt; BMY 26517 
BMY 26517 
potassium 9-methyl-3-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)pyrido[1,2-a]pyrimidin-4-one 
CAS-100299-08-9 
NCGC00167434-01 
Pemilaston (TN) 
Alegysal (TN) 
Alamast (TN) 
AC1L9FCU 
TBX, Pemirolast Potassium 
AC1Q1U3A 
Alamast, Pemirolast potassium 
BMY-26517 
C10H7KN6O 
SCHEMBL865789 
C10H9N6O.K 
CHEMBL1201050 
DTXSID7046623 
CTK8E7454 
pemirolast-bmy-26517-potassium 
NMMVKSMGBDRONO-UHFFFAOYSA-N 
HMS3713G17 
BMY26517 
pemirolast 
Pemirolast potassium (JP17/USAN) 
Tox21_112438 
DE-068 
Pemirolast (BMY 26517) potassium 
s4008 
AKOS015901748 
Tox21_112438_1 
AC-8303 
AN-8120 
API0003772 
pemirolast potassium salt 
CCG-220358 
HS-0020 
Pemirolast potassium, >=98% (HPLC) 
SB18793 
VA11504 
NCGC00167434-02 
AC-22387 
H445 
LS-134189 
RT-014978 
PEMIROLAST POTASSIUM 
FT-0631005 
P1995 
P2547 
D01088 
299P089 
J-000087 
I14-14049 
kalium-5-(9-methyl-4-oxo-4h-pyrido[1,2-a]pyrimidin-3-yl)tetrazol-1-id 
9-methyl-3-(1H-tetrazol-5-yl)-4H-pyridol[1,2-alpha]pyrimidin-4-one, potassium salt 
9-Methyl-3-(2H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-one Potassium Salt 
100299-08-9 
C10H7N6O.K 
C10-H7-N6-O.K 
CID57696 
CID443866 
B1563 
4H-Pyrido[1,2-a]pyrimidin-4-one, 9-methyl-3-(2H-tetrazol-5-yl)-, potassium salt (1:1) 
10-METHYL-4-(2H-TETRAZOL-5-YL)-2,6-DIAZABICYCLO[4.4.0]DECA-1,3,7,9-TETRAEN-5-ONE POTASSIUM 
Pemilaston 
Literature

Title: Pemirolast reduces cisplatin-induced kaolin intake in rats.

Journal: European journal of pharmacology 20110701

Title: [Toxicity of topical ocular anti-allergic agents on human corneal epithelial cells in vitro].

Journal: [Zhonghua yan ke za zhi] Chinese journal of ophthalmology 20100101

Title: Suppressive activity of pemirolast potassium, an antiallergic drug, on glomerulonephritis. Studies in glomerulonephritis model rats and in patients with chronic glomerulonephritis concurrently affected by allergic rhinitis.

Journal: Arzneimittel-Forschung 20080101

Title: The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis.

Journal: Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde 20080101

Title: A late cutaneous response in actively sensitized rats: a new method for evaluating the efficacy of antiallergic drugs.

Journal: Journal of pharmacological sciences 20060801

Title: Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer.

Journal: International journal of cancer 20060515

Title: Tetrazole compounds: the effect of structure and pH on Caco-2 cell permeability.

Journal: Journal of pharmaceutical sciences 20060401

Title: Peripheral interstitial keratitis: a novel manifestation of ocular mastocytosis.

Journal: Cornea 20060401

Title: Comparison of antigen-induced leukotriene and histamine release from nasal scrapings in allergic rhinitis.

Journal: Rhinology 20050901

Title: Increasing effect by simultaneous use of levocabastine and pemirolast on experimental allergic conjunctivitis in rats.

Journal: Biological & pharmaceutical bulletin 20050301

Title: Pemirolast potently attenuates paclitaxel hypersensitivity reactions through inhibition of the release of sensory neuropeptides in rats.

Journal: Neuropharmacology 20040501

Title: A comparative trial of the safety and efficacy of 0.1 percent pemirolast potassium ophthalmic solution dosed twice or four times a day in patients with seasonal allergic conjunctivitis.

Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20040401

Title: Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis.

Journal: Japanese journal of ophthalmology 20040101

Title: Preventive effect of an antiallergic drug, pemirolast potassium, on restenosis after stent placement: quantitative coronary angiography and intravascular ultrasound studies.

Journal: Journal of cardiology 20030701

Title: A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents.

Journal: Clinical therapeutics 20030401

Title: Two mast cell stabilizers, pemirolast potassium 0.1% and nedocromil sodium 2%, in the treatment of seasonal allergic conjunctivitis: a comparative study.

Journal: Advances in therapy 20030101

Title: Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies.

Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20021001

Title: Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells.

Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 19971201

Title: A pilot study of pemirolast in patients with seasonal allergic rhinitis.

Journal: Annals of allergy 19910201

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Additional Info:
Q & A
Related Products